ESC/EACTS Guidelines on Valvular Heart Disease: Key Changes

You should note that the 2024 ESC/EACTS guidelines put the heart‑team at the core of every severe valvular decision. They also mandate coronary CTA for all patients before any valve intervention. TAVI is now class I for adults 70 years, yet SAVR remains primary for octogenarians bicuspid valves; class‑I TEER applies, a nuance you’ll appreciate. For aortic regurgitation, TAVI applies only to high‑risk patients with favorable anatomy, achieving >90 % success. Secondary MR TEER; TMVR tackles MAC, discover.

Table of Contents

Key Takeaways

All severe valvular cases must be managed by a multidisciplinary Heart‑Team, with decisions documented and consensus reached.
Patients requiring valve intervention must be referred to certified high‑volume centres with hybrid cath labs and 24/7 surgical backup.
Comprehensive imaging—3‑D TTE, CCT, CMR, and coronary CTA—has become mandatory for pre‑procedural planning and device selection.
Aortic stenosis now permits TAVI in anatomically suitable patients ≥70 years, irrespective of risk, while SAVR remains first‑line for octogenarians and bicuspid valves.
Primary MR requires early surgical repair in low‑risk patients; secondary MR is treated with TEER (Class I) per COAPT criteria.

What’s New in 2024 Valve Guidelines?

The 2024 ESC/EACTS guidelines introduce several pivotal changes that refine valve‑disease management through a stronger emphasis on multidisciplinary coordination and evidence‑driven therapy selection. You’ll see the Heart Team’s central role underscored; every severe valvular case must involve cardiology, imaging, interventional, and surgical experts, with shared decision‑making mandatory. High‑volume valve centres become the default referral point, as data link experience to superior outcomes. Risk Stratification anchors TAVI eligibility: the age cut‑off drops to 70 for aortic stenosis, yet you’ll favor TAVI over SAVR only when anatomy, lifetime strategy, and redo options align. Imaging Innovation emerges as a cornerstone; expanded 3‑D echo, CCT, CMR are mandated for screening, evaluation, and integrative phenotyping, with standardized acquisition and reporting to guarantee Heart Team trust. For mitral disease, Class I recommendations shift toward early repair in low‑risk asymptomatic patients and TEER for secondary MR without CAD, reflecting new trials that favor less invasive approaches.

Moreover, the guidelines now mandate coronary CTA before all valve interventions to rule out CAD, a step classified as class I, LoE B.

TAVI at 70 Years: When and Why It’s Preferred for Aortic Stenosis

How does the 2024 ESC/EACTS guideline shift TAVI eligibility at age 70? It expands the offer to all anatomically suitable patients 70 years or older, regardless of calculated surgical risk. This Class I recommendation (level B) builds on randomized trials—NOTION, PARTNER 3, Evolut LR, OBSERVANT—that show no excess morbidity in low‑risk cohorts and superior composite outcomes in 1‑year follow‑up. When you assess anatomy suitability by valve morphology and annular dimensions, you must weigh risk assessment against frailty and comorbidities. Low ejection fractions (50 % at 12 months. Pulmonary hypertension remains a predictor of mortality, demanding meticulous Heart Team deliberation. For octogenarians, TAVI remains first‑line, while bicuspid valves still favor SAVR due to PVL risks. Your decisions hinge on patient life‑expectancy versus valve durability and anticipate 10 to 15‑year durability in younger cohorts for ideal outcomes.

advanced imaging such as 3 D echo, CCT, and CMR are increasingly pivotal for screening and evaluating valvular disease.

Choosing TAVI vs. SAVR in Aortic Regurgitation: Current Criteria

When clinicians evaluate patients with severe aortic regurgitation, they must align their treatment plan with the ESC and ACC consensus that designates SAVR as the default choice for operable individuals, limiting TAVI to those who are high‑risk or present favorable anatomy. You must first perform rigorous calcification assessment and annular sizing using multidetector CT and echocardiography. ESC guidelines recommend SAVR when the valve is heavily calcified, the annulus exceeds 28 mm, or when the left ventricular outflow tract is at risk of embolization. TAVI becomes the principal alternative in patients who are surgically high‑risk, have favorable annular geometry, and present low calcific burden. Although cardiac mortality remains similar between TAVI and SAVR, the long‑term durability advantage of SAVR is prominent, especially in those under 60 with preserved LVEF. When you select TAVI, confirm minimal paravalvular leak risk by choosing devices with sealing and confirming adequate oversizing during annular sizing. In recent trials, dedicated AR‑specific TAVR devices such as the JenaValve Trilogy have achieved technical success rates exceeding 90%, markedly reducing the risk of valve embolization compared with conventional devices.

Primary Mitral Regurgitation: Early Surgical Repair for High‑Risk Patients

Because early surgical repair in adults with severe primary mitral regurgitation improves survival and preserves left‑ventricular geometry, clinicians should now follow the ESC’s Class I recommendation to intervene even in asymptomatic low‑risk patients who meet strict quantitative thresholds (LVEF > 60 %, ESD 95 % repair success and <1 % operative mortality. Notably, the ESC guideline now sets the TAVI eligibility age cut-off at 70 yrs, reflecting recent trial data. Prioritize repair timing by integrating imaging metrics and risk scores into decision‑making. Patient selection hinges on valve morphology, LV dimensions, and comorbid burden; missed subclinical dysfunction delays intervention, reducing durability. At heart‑valve centres, invasive techniques lower postoperative atrial fibrillation and accelerate recovery, enabling timely surveillance. Operative mortality stays under 1 % with evidence‑based protocols, and repair durability exceeds 10 years in patients. For high‑risk candidates, TEER offers a safe bridge but yields inferior outcomes; the Heart Team must reassess candidacy using serial echocardiography and clinical indices. Consistent application of these criteria maximizes benefit and aligns with guideline evolution.

Secondary MR: TEER Gaining Class I Evidence for Ventricular and Atrial Forms

Recent ESC/EACTS guidance now classifies transcatheter edge‑to‑edge repair (TEER) as a Class I, Level A intervention for symptomatic secondary mitral regurgitation, encompassing both ventricular and atrial phenotypes. You will see that this elevation aligns with COAPT‑derived anatomy, where pre‑procedural ejection fraction of 20‑50 %, left‑ventricular end‑systolic dimension ≤70 mm, and pulmonary artery systolic pressure ≤70 mm Hg predict benefit. The guideline also acknowledges the divergent MITRA‑FR findings, prompting a stricter regurgitant threshold: EROA ≥40 mm² (or 30 mm² via 2‑D PISA) now defines severe SMR. These thresholds resolve the long‑standing threshold debate and narrow eligibility to patients with demonstrable mechanical interference. Atrial SMR receives parallel treatment, with TEER supported for symptomatic cases lacking coronary artery disease; imaging must confirm annular dilation and minimal ventricular involvement. Ultimately, you should use multi‑modal assessment, reserve surgery for TEER‑ineligible patients, and follow the evidence‑based Class I recommendation. Your clinical decisions should incorporate updated imaging protocols, shared‑decision‑making, and multidisciplinary oversight guidelines today. ESC/EACTS also provides a Class IIb recommendation for TEER in advanced heart‑failure patients being considered for LVAD or transplant, but it specifically excludes those with a left‑ventricular ejection fraction below 20 %.

Transcatheter Mitral Valve‑in‑Valve for Severe MAC: New High‑Risk Option

Although transcatheter mitral valve‑in‑Valve (TMVR) emerged as an off‑label strategy for severe mitral annular calcification (MAC), the MITRAL trial’s 80 % technical success and expanding device options now position it as a viable high‑risk therapy. The registry data indicate that technical success technical success increased notably with operator experience, rising from 62.5% to 84.4% in the second tertile and stabilizing at 80% in the third. You will observe that valve‑in‑MAC procedures rely on balloon‑expandable Sapien XT or Sapien 3 valves, anchored by the dense calcification pattern of the D‑shaped annulus. In your cohort of elderly, comorbid patients, the risk of left ventricular outflow tract (LVOT) obstruction remains the most formidable complication, occurring in 6.7 % of cases. Careful imaging—planning for circularization to minimize paravalvular leak—is essential. Despite a 9.5 % in‑hospital mortality, meta‑analyses demonstrate 87 % procedural success versus 94 % in lower‑calcification groups. Over 12 months, you’ll find that residual MR stays ≤ mild, gradients average 7.3 mmHg, and one‑year mortality drops to 26 % among MAC patients, supporting TMVR as an evolving high‑risk alternative for multidisciplinary care and robust patient selection effectively.

Heart‑Valve Centres: Mandatory Networks for Optimised Outcomes

If you’re convinced that high procedural volume and fully integrated multidisciplinary teams lower operative mortality, the rationale for mandatory heart‑valve centres and coordinated regional networks follows naturally. As a clinician, you should adopt the ESC/EACTS definition, whereby a centre of excellence delivers patient‑centred care across the entire spectrum of surgical and transcatheter valve procedures. You must meet Volume Standards that prescribe high case numbers for both the hospital and individual operators, ensuring that every procedure benefits from specialized training. Network Integration is critical; a 24/7 institutional cardiology and cardiac surgery department, coupled with hybrid catheterisation labs and multimodality imaging, creates an environment where a core Heart Team—including cardiologist, interventionalist, surgeon, imaging specialist, and anaesthesiologist—convenes regularly under standard operating procedures. Structured Heart Valve Clinics facilitate timely referral, early detection of worsening symptoms, and thorough follow‑up. Continuous data auditing and registry participation guarantee adherence to guideline‑based care and continuous improvement. Adhering to these standards sharpens outcomes for all patients. The establishment of specialty Heart Valve Centres should be made mandatory for managing complex valvular heart disease to ensure optimal patient outcomes.

Frequently Asked Questions

Are There Guideline Indications for Valve Replacement in Pregnant Patients With Severe Aortic Stenosis?

Yes, you need to replace the valve. When a pregnant patient shows severe aortic stenosis, the risk to her and to fetal safety rises sharply, so guidelines recommend intervention—preferably surgical aortic valve replacement with ascending‑aorta plasty—before conception. If that’s not feasible, you can consider balloon valvuloplasty or TAVI in later trimesters, but these carry higher pregnancy risk and limited evidence.

How Do the Guidelines Address Transcatheter Treatment of Isolated Mitral Annular Calcification Without Stenosis?

You’re about to uncover a quiet omission: the 2025 ESC/EACTS Council doesn’t endorse transcatheter treatment for isolated mitral annular calcification (MAC) lacking stenosis. Evidence shows no formal recommendation, nor a validated risk score for MAC. While Transcatheter Feasibility remains theoretically possible, Calcification Assessment via advanced CT is required to gauge anchor integrity and anatomical suitability. Consequently, patient selection rests on individual anatomical and frailty evaluation, not guideline precedent currently today.

What Are the Recommendations for Lv‑Ad Implantation in Severe Mitral Regurgitation?

Implementing LV‑AD support in severe mitral regurgitation is reserved for high‑risk surgical candidates or those with refractory heart failure. You should evaluate right‑ventricular function, pulmonary pressures, and MR severity to anticipate LV‑AD‑induced volume unloading. Durability Concerns dictate that the device should function as a bridge to recovery or transplant, not a long‑term fix. Anticoagulation strategy requires therapeutic INR or PTT maintenance, with periodic echocardiographic surveillance for thrombus or regurgitant changes.

Is There a Class I Recommendation for Valve Repair in Patients With Infective Endocarditis?

Imagine you’re a seasoned gardener in a war‑torn valley, planting resilient roots amid shifting winds. In that scene, you’ll find there is currently no Class I recommendation for valve repair in infective endocarditis. Current guideline wording favors replacement or staged interventions, citing moderate evidence strength. Studies show variable clinical outcomes, with repair often limited to select anatomical contexts. Thus, you must weigh individual anatomy, infection severity, and evidence before deciding now.

How Does the Guideline Advise Managing Asymptomatic Bicuspid Aortic Valve Degeneration?

You manage asymptomatic bicuspid aortic valve degeneration by scheduling surveillance intervals that depend on valve velocity and calcification burden. You’re urged to limit high‑intensity exercise when Vmax exceeds 5 m/s or mean gradient surpasses 60 mmHg. You intervene early if LVEF drops below 55 % or BNP rises triple the norm. The heart‑team approach guides TAVI eligibility, ensuring timely, evidence‑based valve replacement. You monitor symptoms continuously, yearly, adjusting therapy if progression occurs immediately.

Conclusion

You’re poised at the precipice of a transformative era in valvular heart disease management. The 2024 guidelines reframe TAVI as the default for 70‑year‑old aortic stenosis, while delineating strict criteria for TAVI versus SAVR in aortic regurgitation. Early repair is now mandatory for high‑risk primary MR, and TEER achieves Class I status for both ventricular and atrial secondary MR. Yet, the ultimate challenge remains: how will these evolving thresholds shape your next future critical definitive intervention?

References

admin